

UNITED STATES PATENT AND TRADEMARK OFFICE

BEFORE THE PATENT TRIAL AND APPEAL BOARD

MYLAN PHARMACEUTICALS INC.,
Petitioner

v.

BOEHRINGER INGELHEIM INTERNATIONAL GMBH,
Patent Owner.

Case IPR2016-01566
Patent 9,173,859 B2

Filed: December 1, 2016

DECLARATION OF CHARLES A. NAGGAR
IN SUPPORT OF MOTION FOR ADMISSION
PRO HAC VICE

IPR2016-01566

Mylan Ex. 1019, Page 1

I, Charles A. Naggar, hereby declare under penalty of perjury:

1. I am an attorney with the law firm of Alston & Bird LLP. I have been a practicing attorney since 2015.

2. I am a member in good standing of the Bar of the State of New York.

3. I have never been suspended or disbarred from practice before any court or administrative body.

4. I have never been denied admission to practice before any court or administrative body.

5. I have never been subject to sanctions or contempt citations imposed by any court or administrative body.

6. I have read and will comply with Office Patent Trial Practice Guide and the Board's Rules of Practice for Trials, as set forth in title 37, part 42 of the Code of Federal Regulations (C.F.R.).

7. I agree to be subject to the United States Patent and Trademark Office Rules of Professional Responsibility set forth in parts 10 and 11 of 37 C.F.R. and to disciplinary jurisdiction under 37 C.F.R. § 11.19(a).

8. I have not appeared *pro hac* vice in any proceedings before the United States Patent and Trademark Office in the past three (3) years. I am, however, filing concurrent motions for *pro hac* vice admission in the following proceedings: IPR2016-01563, IPR2016-01564, and IPR2016-01565.

9. I am an experienced litigating attorney and have specific experience in patent law and patent litigation. I have represented clients in numerous patent infringement actions across the country in various technical areas, including actions involving medicine, pharmaceuticals, medicinal chemistry, drug development, and methods of treatment.

10. I have an established familiarity with the subject matter at issue in this proceeding. Specifically, I have reviewed the challenged patent, the Petition, and the accompanying exhibits and am familiar with the relevant prior art. As a result of my representation of Petitioner in *Boehringer Ingelheim Pharmaceuticals Inc. et al v. HEC Pharm Co., Ltd. et al*, Case No. 3:15-cv-05982-PGS-TJB (D.N.J.), I have acquired substantial understanding of the technology at issue in this IPR.

Pursuant to 28 U.S.C. § 1746, I declare under penalty of perjury that the foregoing is true and correct and that all statements made herein of my own knowledge are true and that all opinions expressed herein are my own; and further that these statements were made with the knowledge that willful false statements and the like are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code and that such willful false statements may jeopardize the validity of the application or any patent issued thereon.

/ Charles A. Naggar /
Charles A. Naggar

December 1, 2016
Date

Case IPR2016-01566
Patent 9,173,859 B2

CERTIFICATE OF SERVICE

Pursuant to 37 C.F.R. §42.6(e), the undersigned hereby certifies that, on the 1st day of December, 2016 a complete copy of the foregoing “DECLARATION OF CHARLES A. NAGGAR IN SUPPORT OF MOTION FOR ADMISSION *PRO HAC VICE*” was served via e-mail on counsel for Patent Owner:

Leora Ben-Ami (Reg. No. 32455)
Email: leora.benami@kirkland.com
KIRKLAND & ELLIS LLP
601 Lexington Avenue
New York, New York 10022
Tel: (212) 446-4800
Fax: (212) 446-4900

Eugene Goryunov (Reg. No. 61,579)
Email: eugene.goryunov@kirkland.com
KIRKLAND & ELLIS LLP
300 North LaSalle
Chicago, Illinois 60654
Tel: (312) 862-2000
Fax: (312) 862-2200

Jeanna Wacker (*Pro Hac Vice* Pending)
Email: jeanna.wacker@kirkland.com
KIRKLAND & ELLIS LLP
601 Lexington Avenue
New York, New York 10022
Tel: (212) 446-4800
Fax: (212) 446-4900

Mira Mulvaney (Reg. No. 69,850)
Email: mira.mulvaney@kirkland.com
KIRKLAND & ELLIS LLP
601 Lexington Avenue
New York, New York 10022
Tel: (212) 446-4800

Case IPR2016-01566
Patent 9,173,859 B2

Fax: (212) 446-4900

Dated: December 1, 2016

/ Thomas J. Parker /

Thomas J. Parker
(Reg. No. 42,062)